Ernexa Therapeutics Inc recorded a cumulative net loss of $-12 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 363 other companies achieving higher income per employee. While Ernexa Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 3608 to 4039.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ERNA Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-2,451,600	-2,277,600	-2,816,800	-3,668,000	-8,740,800
ERNA's Total Ranking	# 4039	# 3608	# 3800	# 3252	# 3344
Seq. Net Income Change	-	-	-	-	-

ERNA Company Profile >> Back to ERNA Efficiency Comparisons >> Compare ERNA Net Income per Employee to its Competitors

ERNA Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 364
Healthcare Sector	# 806
Overall Market	# 4039

Net Income per Employee Statistics
High	Average	Low
$ 43,000	$ -3,621,807	$ -24,509,000
(Jun 30 2013)		(Dec 31 2021)

News about Ernexa Therapeutics Inc Income per employee

Eterna Therapeutics Secures $9.2 Million Convertible Debt and Warrant Financing to Propel mRNA Cell Engineering Capabilities.

Eterna Therapeutics: Secures $9.2 Million Funding for Advancing mRNA Cell Engineering
CAMBRIDGE, Mass., Dec. 14, 2023 - Eterna Therapeutics Inc. (Nasdaq: ERNA), a leading life science company focused on harnessing the potential of mRNA cell engineering to develop revolutionary new medications, recently disclosed the execution of a securities purchase agreement with accredited investors. The agreement involves the sale of approximately $9.2 million in senior convertible promissory notes, coupled with accompanying warrants to acquire 9,579,014 shares of common stock, through a private placement transaction that adheres to Nasdaq rules for at-the-market pricing. The initial closing is anticipated to occur on December 15, 2023, generating proceeds of around $7.8 million, with the remaining funds expected to be received by January 15, 2023.
This financing event serves as a significant milestone for Eterna Therapeutics, facilitating the company s continued growth and advancement of its mRNA cell engineering capabilities. The funds will be utilized to support ongoing research and development efforts, enabling the discovery and development of groundbreaking medicines that hold immense potential for patients.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Jun 30 2026

Number of Employees Jun 30 2026

Date modified: 2026-09-08T17:34:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.